Proving the Clinical Efficacy of SV-102 in Multiple Cancer Indications
Time: 1:00 pm
day: Conference Day Two
Details:
- Transforming the personalized cancer space by freezing tumors in situ, lysing and releasing the neoantigens to activate T cells
- Employing a two-pronged attack with a cocktail of checkpoint inhibitors in the same local environment for maximum patient effect
- Demonstrating the viability of this personalized cancer therapy in metastatic prostate cancer and beyond
